Race Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Race Oncology wird ein Gewinn- und Umsatzwachstum von 0.1% bzw. 34.8% pro Jahr prognostiziert, während der Gewinn pro Aktie sinken soll.

Wichtige Informationen

0.1%

Wachstumsrate der Gewinne

-40.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.3%
Wachstumsrate der Einnahmen	34.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	29 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07

Gewinn- und Umsatzwachstumsprognosen

ASX:RAC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	11	-7	-6	-6	1
6/30/2026	3	-27	-27	-27	1
6/30/2025	5	-6	-6	-6	1
6/30/2024	4	-14	-10	-10	N/A
3/31/2024	5	-12	-11	-11	N/A
12/31/2023	6	-11	-13	-13	N/A
9/30/2023	4	-11	-12	-12	N/A
6/30/2023	3	-10	-11	-11	N/A
3/31/2023	2	-10	-10	-10	N/A
12/31/2022	1	-11	-9	-9	N/A
9/30/2022	1	-11	-8	-8	N/A
6/30/2022	1	-11	-6	-6	N/A
3/31/2022	1	-10	-6	-6	N/A
12/31/2021	1	-9	-6	-6	N/A
9/30/2021	1	-8	-5	-5	N/A
6/30/2021	0	-6	-5	-5	N/A
3/31/2021	0	-5	-4	-4	N/A
12/31/2020	0	-4	-3	-3	N/A
9/30/2020	0	-4	-3	-3	N/A
6/30/2020	0	-4	-2	-2	N/A
3/31/2020	0	-3	-2	-2	N/A
12/31/2019	0	-3	-2	-2	N/A
9/30/2019	0	-3	-2	-2	N/A
6/30/2019	0	-4	-3	-3	N/A
3/31/2019	0	-4	-3	-3	N/A
12/31/2018	0	-5	-3	-3	N/A
9/30/2018	0	-6	-3	-3	N/A
6/30/2018	0	-6	-4	-4	N/A
3/31/2018	0	-6	N/A	-4	N/A
12/31/2017	0	-6	N/A	-4	N/A
9/30/2017	0	-5	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-3	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	N/A	-1	N/A	-1	N/A
6/30/2016	N/A	0	N/A	0	N/A
3/31/2016	N/A	0	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
9/30/2015	N/A	0	N/A	0	N/A
6/30/2015	N/A	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RACDie Einnahmen des Unternehmens (34.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.7% pro Jahr).

Hohe Wachstumseinnahmen: RACDie Einnahmen des Unternehmens (34.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RAC in 3 Jahren voraussichtlich hoch sein wird

Race Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 12%

Price target increased by 26% to AU$3.22

Recent updates

Race Oncology Limited, Annual General Meeting, Nov 25, 2024

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited

Race Oncology Limited Appoints Mary Harney as Non-Executive Director

New 90-day high: AU$2.48

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Race Oncology Limited Announces Borje Andersson Resigns as an Executive Director